WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer

- Dr. Vinocur Reports on University of California Rosacea-Specific Study -

NAPA, Calif., March 13 /PRNewswire-FirstCall/ – On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University of Maryland School of Medicine, was featured on WBAL-AM 1090 in a segment on rosacea, a condition afflicting over 14 million Americans. Dr. Vinocur addressed current therapies while reporting on a new study conducted at the Department of Dermatology, University of California, Irvine, in which rosacea patients were treated with a new cosmeceutical, Pyratine XR(TM) (0.125% furfuryl tetrahydropyranyl adenine).

Rosacea is a chronic skin disorder characterized by dilated blood vessels on the face, redness, inflammation, and lesions (papules and pustules). According to Dr. Vinocur, traditional treatments for rosacea focus on topical and oral antibiotics for their anti-inflammatory properties, but the new study showed that cytokinins, natural plant-derived growth factors known for their antioxidant and moisture retention benefits, appear to significantly reduce rosacea symptoms.

Over the 48-week study with Pyratine XR(TM) there was an overall clinical improvement in 80% of subjects with a 90% improvement in lesions, 45% improvement in redness, and a 28% improvement in spider veins. The product also appeared to improve the skin barrier function with a 41% improvement in skin dryness as early as week four while appearing to concurrently reduce fine lines, wrinkles and hyperpigmentation.

Pyratine XR(TM) is manufactured by Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging. Pyratine XR(TM) officially launched at the American Academy of Dermatology’s 67th Annual Meeting in San Francisco, March 6-10, 2009.

For more information on Pyratine XR(TM), please visit www.PyratineXR.com.

About Senetek, PLC

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company’s website at www.senetekplc.com.

SOURCE Senetek PLC